Telix Pharmaceuticals (ASX:TLX) named New York Stock Exchange-listed healthcare company Cardinal Health as one of the commercial radiopharmaceutical distributors of its prostate cancer imaging agent, Gozellix, according to a Tuesday statement.
Gozellix is slated for commercial launch in the first half of this year. The agreement will enable Cardinal Health to supply finished unit doses of Gozellix using Telix's Aartms Quantm Irradiation System cyclotron technology, per the statement.
The imaging agent received the US Food and Drug Administration's approval in March.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。